Biomarkers for the Surgical Treatment of Rotator Cuff Tears
- Conditions
- Rotator Cuff Tears
- Registration Number
- NCT02123784
- Lead Sponsor
- Balgrist University Hospital
- Brief Summary
Identification of biomarkers that can predict the outcome of the surgical treatment (i.e. the rate of re-rupture) of tears in the rotator cuff tendon.
- Detailed Description
Rotator cuff tears (i.e. structural failure and tissue disruption in at least one of the four muscles and tendons that form the rotator cuff) are extremely common injuries and represent the most common muscle-tendon tear in patients. Repair of rotator cuff tears is usually advocated for painful tears with functional impairment. However, high failure rates of 13-68% have been reported for surgical repair of rotator cuff tears, irrespective of the surgical technique employed. Higher rates of re-rupture are associated with larger tears, increased patient age, and increased fatty degeneration of the cuff muscles. There is no general consensus as to the causes of re-rupture; where mechanical factors, the existing techniques of suturing, and biological factors are considered as the main factors of recurrence.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Full-thickness rotator cuff tear (isolated transmural supraspinatus muscle tear or combined with infraspinatus and subscapularis tears) with fat content <50% (Goutallier stage 0-2), as confirmed by magnetic resonance imaging
- Acute or chronic ruptures
- Older than 40 years of age
- Voluntary participation in this study
- Written informed consent to participate in this study
- Contraindication because of ethical reasons
- Pregnant or lactating women
- Intention/wish to become pregnant during the course of this study
- Unsafe contraception
- Clinical co-morbidities, such as renal insufficiency, hepatic dysfunction, cardiovascular disease
- Known or suspected non-adherence to the study protocol
- Smoker
- Drug or alcohol addicted
- Uncapable of following instructions, e.g. because of insufficient proficiency in languages, psychological problems, dementia, etc.
- Participation in other clinical trials during the duration of this study, as well as 30 d before inclusion in this study
- Claustrophobia
- Systemic corticoid steroid therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes from baseline for anatomical and functional characteristics of the ruptured rotator cuff Before surgery (baseline), 3 months after surgery, 12 months after surgery Patients will undergo a clinical and functional examination which includes the assessment of mobility, pain and abduction force of the affected and healthy shoulder using standardized tests (Constant score, Quick DASH, Quality of Life Score SF-12), the quantification of the volume (cm3) and fat content (Goutallier Stage) of the affected shoulder using magnet resonance imaging.
Molecular and cellular characteristics of the tissues affected by tears of the rotator cuff within 1 year after the last surgery Before the surgery 10 mL of venous blood will be drawn from the patients and processed for the isolation of genomic DNA and the measure of selected single nuclear polymorphisms.
Biopsies (\~10 mg) will be collected intra-operatively from the affected muscle, tendon, capsule and synovial liquid and stored at -80°C. Samples will be subjected to the immunohistochemical and biochemical quantification of the content (in arbitrary units) of selected proteins and tissue composition (as % of total volume).
- Secondary Outcome Measures
Name Time Method Correlation between the molecular and cellular characteristics at the point in time of surgery, and the clinical (magnetic resonance imaging) outcomes within 1 year after the last surgery The relationship of the molecular and cellular parameters (measured as primary endpoints) of affected muscle with the clinical and functional measures of shoulder function will be investigated using Pearson correlation and mutual information analysis.
Trial Locations
- Locations (1)
Balgrist University Hospital
🇨🇭Zurich, Switzerland